Company Overview and News

 
Parkson Holdings sells 70% stake in Parkson Credit

2018-09-14 theedgemarkets
KUALA LUMPUR: Parkson Holdings Bhd is divesting a 70% stake in its wholly-owned hire purchase unit, Parkson Credit Sdn Bhd, to Hong Kong-listed subsidiary Parkson Retail Group Ltd for RM49 million.
5657 5228 PKSGF PKSGY 3368 BSMAF 1818

 
ELK-Desa Resources kicks off FY19 on a positive note

2018-08-17 theedgemarkets
KUALA LUMPUR (Aug 17): ELK-Desa Resources Bhd, which saw its first-quarter net profit jump 59.8% year-on-year (y-o-y), is confident that its performance for the financial year ending March 31, 2019 (FY19) will be better than FY18.
5228

 
Stock With Momentum: Elk-Desa Resources

2018-08-14 theedgemarkets
TRADING of shares in Elk-Desa Resources Bhd (fundamental: 2.3/3, valuation: 2.6/3) triggered our stocks with momentum algorithm yesterday for the first time this year.
5228

 
ELK-Desa hopes to maintain 15% CAGR growth in FY19

2018-08-10 theedgemarkets
KUALA LUMPUR: ELK-Desa Resources Bhd expects its 15% compound annual growth rate (CAGR) in the last five financial years to spill over into the current year, as it seeks to grow the hirer base and is supported by higher financial leverage through bank borrowings.
5228

 
ELK-Desa confident of sustaining strong growth momentum

2018-08-09 theedgemarkets
KUALA LUMPUR (Aug 9): Focused on the used-car segment, non-bank lender ELK-Desa Resources Bhd is confident it can continue to sustain its robust growth momentum in the small value financing segment which is underserved.
5228

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...